Economic burden associated with adenomyosis extends beyond direct medical costs to encompass substantial indirect expenses related to productivity losses, disability, and reduced quality of life affecting both patients and society broadly. Comprehensive cost analyses must capture multiple expense categories including diagnostic evaluations, pharmaceutical therapies, surgical...